Chinese Medicine Herbal Extract Inhibits COVID-19 Infection

Listen to this News

Highlights:

• Bioactive components from Ganoderma lucidum has been found to inhibit SARS-CoV-2 host cell entrance
• This fungus' bioactive extracts exhibit strong immune-stimulating and antiviral properties

One of Ganoderma lucidum's bioactive components, lucidenic acid A, has been found by researchers as a possible inhibitor of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) host cell entrance. A recent issue of the journal Food and Chemical Toxicology included the study.

A variety of bioactive chemicals with anti-inflammatory, antiviral, antioxidative and anticancer properties can be found in abundance in Chinese traditional medicinal herbs. Regarding antiviral efficacy, it has been discovered that bioactive substances extracted from roughly 30 medicinal plants inhibit coronavirus infection via a variety of methods.

‘The extract from Ganoderma lucidum can stop SARS-CoV-2 invasion. It prevents spike protein from binding to the hACE2 receptor.’

By modifying immunological response and protease activity, fungus bioactive substances such as polysaccharides, terpenes, and cordycepin have demonstrated antiviral efficacy against coronavirus.

The Polyporaceae family includes the common Chinese medicinal fungus known as Ganoderma lucidum. This fungus' bioactive components have been extracted, and they exhibit strong immune-stimulating and antiviral properties.

By blocking the connection between the viral spike protein and the host cell receptor angiotensin-converting enzyme 2, researchers have examined whether Ganoderma lucidum can stop SARS-CoV-2 host cell entry (ACE2).

Antiviral Properties of Ganoderma lucidum

The initial screening of Ganoderma lucidum resulted in the discovery of 574 antiviral target proteins and 54 bioactive chemicals. With the help of these targets and SARS-CoV-2-specific targets, 80 anti-SARS-CoV-2 targets from Ganoderma lucidum were found.

The targets associated with inflammation, infection, cancer, and other pathways were integrated into a network model of Ganoderma lucidum's putative antiviral target genes. Scientists proposed that the bioactive chemicals might be employed to treat SARS-CoV-2 infection based on the actions of the identified targets.

Each antiviral compound of Ganoderma lucidum can act on many targets, according to the analysis of the target-compound network. More specifically, it was discovered that 54 identified chemicals interacted with 80 SARS-CoV-2-related targets. Furthermore, associations between these targets and 20 distinct signalling pathways were discovered. The bulk of these pathways was antiviral and anti-inflammatory.

Dynamics of bioactive compound interactions

By docking each discovered compound independently with the human ACE2, wildtype spike-human ACE2 complex, and omicron spike-human ACE2 complex, the interaction pattern of each drug was identified. This resulted in the discovery of lucidenic acid A, which showed a high affinity for binding to all target receptors.

It was discovered that lucidenic acid A formed a hydrogen bond with human ACE2 when it interacted with it, preventing the viral spike protein from interacting with ACE2. Overall, these findings suggest that lucidenic acid A can effectively prevent wild-type SARS-CoV-2 and its variations from entering host cells.

Activity of lucidenic acid A against viruses

The spike-ACE2 complex is made unstable by lucidenic acid A, according to the results of a molecular dynamics simulation. This emphasizes even further how effective lucidenic acid A is at preventing spike-ACE2 interaction.

Further investigation revealed that even at low micromolar concentrations, lucidenic acid A inhibits the binding activity of ACE2. This may be how lucidenic acid A primarily works to stop SARS-CoV-2 from infecting host cells.

Antiviral Medicine Against SARS-CoV-2

The study conducts a thorough screening of bioactive chemicals produced from Ganoderma lucidum to find potential antiviral medicines against SARS-CoV-2. Triterpenes and sterols, which are mostly found in discovered substances, have antiviral and anti-inflammatory properties.

Molecular docking tests reveal lucidenic acid A to be a strong anti-SARS-CoV-2 substance with a high affinity for the human ACE2 receptor. At low micromolar concentrations, lucidenic acid A reduces the binding activity of ACE2 in a mechanistic manner. Consequently, this prevents the interaction between human ACE2 and SARS-CoV-2 spike.

Notably, lucidenic acid A blocks the entry of omicron and wild-type SARS-CoV-2 into host cells.

Source: Medindia

Cite this Article ⇣⇡

Please use one of the following formats to cite this article in your essay, paper or report:

• APA

  Dr. Trupti Shirole. (2022, October 04). Chinese Medicine Herbal Extract Inhibits COVID-19 Infection. Medindia. Retrieved on Dec 18, 2024 from https://www.medindia.net/news/indiaspecial/chinese-medicine-herbal-extract-inhibits-covid-19-infection-208789-1.htm.

• MLA

  Dr. Trupti Shirole. "Chinese Medicine Herbal Extract Inhibits COVID-19 Infection". Medindia. Dec 18, 2024. <https://www.medindia.net/news/indiaspecial/chinese-medicine-herbal-extract-inhibits-covid-19-infection-208789-1.htm>.

• Chicago

  Dr. Trupti Shirole. "Chinese Medicine Herbal Extract Inhibits COVID-19 Infection". Medindia. https://www.medindia.net/news/indiaspecial/chinese-medicine-herbal-extract-inhibits-covid-19-infection-208789-1.htm. (accessed Dec 18, 2024).

• Harvard

  Dr. Trupti Shirole. 2022. Chinese Medicine Herbal Extract Inhibits COVID-19 Infection. Medindia, viewed Dec 18, 2024, https://www.medindia.net/news/indiaspecial/chinese-medicine-herbal-extract-inhibits-covid-19-infection-208789-1.htm.